0001209191-23-033780.txt : 20230602 0001209191-23-033780.hdr.sgml : 20230602 20230602163129 ACCESSION NUMBER: 0001209191-23-033780 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230531 FILED AS OF DATE: 20230602 DATE AS OF CHANGE: 20230602 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Simson Jake CENTRAL INDEX KEY: 0001863094 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40800 FILM NUMBER: 23989385 MAIL ADDRESS: STREET 1: C/O JANUX THERAPEUTICS, INC. STREET 2: 11099 N. TORREY PINES ROAD, SUITE 290 CITY: LA JOLLA STATE: CA ZIP: 92037 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Tyra Biosciences, Inc. CENTRAL INDEX KEY: 0001863127 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 831476348 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2656 STATE STREET CITY: CARLSBAD STATE: CA ZIP: 92008 BUSINESS PHONE: (619) 728-4760 MAIL ADDRESS: STREET 1: 2656 STATE STREET CITY: CARLSBAD STATE: CA ZIP: 92008 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-05-31 0 0001863127 Tyra Biosciences, Inc. TYRA 0001863094 Simson Jake C/O TYRA BIOSCIENCES, INC. 2656 STATE STREET CARLSBAD CA 92008 1 0 0 0 0 Stock Option (Right to Buy) 14.47 2023-05-31 4 A 0 14500 0.00 A 2033-05-30 Common Stock 14500 14500 D The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 31, 2023, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), the RA Capital Nexus Fund, L.P. (the "Nexus Fund"), and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, and the Account. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock. /s/ Ali D. Fawaz, Attorney-in-Fact 2023-06-02